ISRG

Over the past six months, Intuitive Surgical's stock has experienced some fluctuations. In Q4 2025, the company reported a 19% year-over-year revenue increase. In Q1 2026, Intuitive Surgical beat Wall Street estimates for profit and revenue. The da Vinci 5 received FDA clearance in 2024 and began its commercial rollout. In Q4 2025, Intuitive Surgical faced challenges in Asia, particularly in China. In Q4 2025, Ion system placements declined significantly. In March 2026, the company disclosed unauthorized access to part of its internal administrative network from a targeted phishing event.